Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Other Non Operating Income (2019 - 2025)

Historic Other Non Operating Income for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $10.4 million.

  • Kymera Therapeutics' Other Non Operating Income rose 770.34% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.5 million, marking a year-over-year increase of 1369.54%. This contributed to the annual value of $38.0 million for FY2024, which is 10265.4% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Other Non Operating Income stood at $10.4 million, which was up 770.34% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Other Non Operating Income registered a high of $10.4 million during Q3 2025, and its lowest value of $98000.0 during Q2 2021.
  • Moreover, its 5-year median value for Other Non Operating Income was $4.6 million (2023), whereas its average is $4.8 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Other Non Operating Income plummeted by 6618.91% in 2021, and later skyrocketed by 253724.14% in 2022.
  • Quarter analysis of 5 years shows Kymera Therapeutics' Other Non Operating Income stood at $145000.0 in 2021, then surged by 2537.24% to $3.8 million in 2022, then soared by 30.65% to $5.0 million in 2023, then surged by 101.4% to $10.1 million in 2024, then rose by 3.8% to $10.4 million in 2025.
  • Its last three reported values are $10.4 million in Q3 2025, $8.1 million for Q2 2025, and $8.9 million during Q1 2025.